Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery

Lantern Pharma Inc. (NASDAQ: LTRN) has announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), a real-time, web-based molecular intelligence engine designed to streamline drug discovery. The enhanced platform, which leverages Lantern’s RADR AI technology, allows researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. It provides high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture, and topological mapping, with benchmark-validated performance. This expansion aims to broaden access to advanced computational tools for the drug development community.

The announcement underscores Lantern’s commitment to integrating artificial intelligence into oncology drug development. The company’s pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.

In addition to its clinical programs, Lantern has commercially launched withZeta.ai, a multi-agentic AI co-scientist platform now available as a subscription-based research platform for the global biomedical community. This represents a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.

The expansion of predictBBB into an LQM is significant because it transforms a targeted platform into a broad, quantitative tool that can be applied to a wide range of small molecules. By making this tool web-based and accessible in real time, Lantern is lowering barriers for researchers who may lack advanced computational resources. The integration with RADR AI ensures that the platform can handle high-dimensional data analysis quickly, potentially reducing the time and cost associated with early-stage drug discovery.

For investors, this development highlights Lantern’s strategic focus on leveraging AI not only for internal pipeline advancement but also as a commercial offering. The subscription model for withZeta.ai and the enhanced predictBBB platform could provide recurring revenue and validate Lantern’s technology beyond its own therapeutic programs. The company’s newsroom provides updates on these developments at https://ibn.fm/LTRN.

Lantern Pharma is a clinical-stage precision oncology company that uses AI and machine learning to transform cancer therapy development. The expansion of its predictBBB platform into a Large Quantitative Model marks a step forward in making sophisticated drug discovery tools more widely available, with potential implications for accelerating the development of new treatments.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery.

The post Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery appeared first on citybuzz.